John Paulson Buys 2,000,000 Shares of Bausch Health Cos Inc. (NYSE:BHC) Stock

Key Points

• John Paulson, a director at Bausch Health Cos Inc., purchased 2 million shares at an average price of $6.35, totaling approximately $12.7 million, raising his stake by 6.1% to over 34.7 million shares.
• Bausch Health's stock has seen a recent 2.5% increase, trading at $7.18, with a market cap of $2.66 billion and a PE ratio of 27.60.
• Despite reporting missing earnings estimates with $0.90 EPS compared to the expected $0.97, the company achieved revenue of $2.57 billion, exceeding predictions of $2.47 billion.

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) Director John Paulson bought 2,000,000 shares of the business's stock in a transaction dated Monday, August 11th. The shares were purchased at an average cost of $6.35 per share, with a total value of $12,700,000.00. Following the completion of the acquisition, the director owned 34,791,702 shares in the company, valued at approximately $220,927,307.70. This represents a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

John Paulson also recently made the following trade(s):

• On Thursday, August 14th, John Paulson acquired 34,721,118 shares of Bausch Health Cos stock. The shares were bought at an average price of $9.00 per share, for a total transaction of $312,490,062.00.
• On Wednesday, August 13th, John Paulson bought 86,409 shares of Bausch Health Cos stock. The shares were purchased at an average cost of $7.06 per share, for a total transaction of $610,047.54.
• On Tuesday, August 12th, John Paulson bought 1,156,640 shares of Bausch Health Cos stock. The stock was bought at an average cost of $6.88 per share, for a total transaction of $7,957,683.20.
• On Friday, June 13th, John Paulson bought 3,564,059 shares of Bausch Health Cos stock. The stock was bought at an average price of $5.94 per share, with a total value of $21,170,510.46.
• On Thursday, June 12th, John Paulson acquired 1,005,376 shares of Bausch Health Cos stock. The stock was purchased at an average price of $5.47 per share, for a total transaction of $5,499,406.72.
• On Wednesday, June 11th, John Paulson acquired 1,029,098 shares of Bausch Health Cos stock. The stock was bought at an average price of $5.24 per share, for a total transaction of $5,392,473.52.
• On Tuesday, June 10th, John Paulson acquired 754,134 shares of Bausch Health Cos stock. The shares were purchased at an average cost of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Cos Stock Performance

BHC traded down $0.26 during trading hours on Monday, hitting $8.09. The company's stock had a trading volume of 1,422,923 shares, compared to its average volume of 2,691,043. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. Bausch Health Cos Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $9.85. The company has a 50-day simple moving average of $6.38 and a 200 day simple moving average of $6.01. The firm has a market capitalization of $2.99 billion, a PE ratio of 31.21 and a beta of 0.41.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. The company had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. As a group, sell-side analysts expect that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Institutional Trading of Bausch Health Cos

A number of institutional investors have recently bought and sold shares of BHC. Goldentree Asset Management LP grew its stake in Bausch Health Cos by 13.2% in the 2nd quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company's stock valued at $227,848,000 after buying an additional 4,004,889 shares during the last quarter. Paulson & CO. Inc. boosted its stake in Bausch Health Cos by 24.0% during the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company's stock valued at $218,393,000 after purchasing an additional 6,352,667 shares during the period. Nomura Holdings Inc. increased its position in Bausch Health Cos by 106.2% in the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company's stock worth $151,366,000 after buying an additional 12,050,000 shares during the period. Vanguard Group Inc. increased its position in Bausch Health Cos by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock worth $76,152,000 after buying an additional 61,621 shares during the period. Finally, Maple Rock Capital Partners Inc. lifted its holdings in shares of Bausch Health Cos by 14.9% during the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company's stock worth $52,005,000 after buying an additional 1,010,987 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BHC shares. Royal Bank Of Canada raised their price objective on shares of Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.